MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.?s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company?s Scientific Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
370 GBX | -1.33% | -0.54% | +4.96% |
May. 08 | MaxCyte Shares Rise Sharply After Q1 Results Beat | MT |
May. 08 | MaxCyte shares rise amid double-digit revenue increase | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.96% | 498M | |
+11.91% | 227B | |
+15.46% | 197B | |
+18.58% | 141B | |
+30.36% | 110B | |
+0.65% | 64.15B | |
+17.74% | 53.72B | |
+5.82% | 51.75B | |
+11.23% | 45.2B | |
+5.73% | 37.37B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer